

INTRODUCTION .....	XXVII
STUDY GOAL AND OBJECTIVES .....	XXVII
REASONS FOR DOING THE STUDY .....	XXVII
CONTRIBUTIONS OF THE STUDY AND FOR WHOM.....	XXVII
SCOPE AND FORMAT .....	XXVIII
METHODOLOGY .....	XXVIII
INFORMATION SOURCES.....	XXVIII
AUTHOR'S CREDENTIALS .....	XXIX
RELATED BCC PUBLICATIONS .....	XXIX
REPORTS .....	XXIX
MONTHLY NEWSLETTERS.....	XXIX
BCC ON-LINE SERVICES.....	XXX
 SUMMARY.....	 XXXI
ORGANS .....	XXXI
TISSUES .....	XXXI
SUMMARY TABLE U.S. ORGAN AND TISSUE TRANSPLANTATION MARKETS, THROUGH 2007.....	XXXII
SUMMARY FIGURE U.S. ORGAN AND TISSUE TRANSPLANTATION MARKETS, 2002 AND 2007 (\$ MILLIONS).....	XXXII
GENERAL TRENDS.....	XXXII
 OVERVIEW .....	 1
IMPORTANCE OF THE INDUSTRY .....	1
ORGANS .....	1
TABLE 1 U.S. ORGAN TRANSPLANTS, AVERAGE 1 <sup>ST</sup> YEAR COST AND MARKET TOTALS, THROUGH 2007.....	1
KIDNEY.....	2
LIVER .....	2
HEART.....	3
LUNG.....	3
INTESTINE.....	4
PANCREAS .....	4
WAITING LISTS .....	5
Waiting Lists Grow Faster than Numbers of Transplantations .....	5
INTERNATIONAL TRENDS .....	5
Limited Supply Puts Breaks on Transplantations .....	6
TABLE 2 NUMBERS OF DONATED CADAVERS BY REGION, 1997-2001 .....	6
TISSUES .....	7
AGING BABY BOOMERS DRIVING MARKET .....	7
TABLE 3 TISSUE GRAFTING IN THE U.S., THROUGH 2007 (NUMBER OF PROCEDURES).....	7
FIGURE 1 ISSUE GRAFTING IN THE U.S., 2002 - 2007 (NUMBER OF PROCEDURES).....	8
CORNEA.....	8

BLOOD STEM CELLS.....	9
BONE ALLOGRAFTS.....	9
HEART VALVES.....	9
VASCULAR TISSUE .....	9
SKIN AND COLLAGEN .....	10
LARGER POTENTIAL MARKETS, SAME LIMITS ON SUPPLY .....	10
<i>TABLE 4 POTENTIAL AND EXPECTED U.S. MARKETS FOR TRANSPLANTED HUMAN TISSUE, THROUGH 2007 (\$ MILLIONS)</i> .....	10
<i>TABLE 4 (CONTINUED)</i> .....	11
WIDESPREAD DISTRUST OF FOR-PROFIT COMPANIES COULD RETARD GROWTH .....	11
MORE REGULATION .....	11
APPLICATIONS.....	11
THE TRANSPLANTATION PROCESS.....	12
PREPARATION .....	12
OPERATION .....	12
RECUPERATION .....	13
MAINTENANCE.....	13
PRODUCTS IN THE TRANSPLANTATION PROCESS.....	13
HLA TISSUE TYPING .....	14
ORGAN PRESERVATION PRODUCTS.....	14
ANTI-REJECTION DRUGS .....	14
ANTIBIOTICS.....	15
POST-TRANSPLANT MONITORING .....	15
ALTERNATIVES TO TRANSPLANTATION.....	15
GOVERNMENT REGULATION AND PATENTS .....	16
EVOLUTION OF TRANSPLANTATION .....	17
TISSUE TYPING .....	17
IMMUNOSUPPRESSION .....	17
PRESERVATION .....	18
GOVERNMENT REIMBURSEMENT OF TRANSPLANTATION COSTS.....	19
MECHANICAL ORGANS.....	19
GENERAL TRENDS.....	20
SUPPLY MANAGEMENT .....	21
REDUCING WASTE AND REJECTION .....	21
INCREASING THE HARVEST .....	21
<i>TABLE 5 RECOVERED ORGANS NOT USED, 1995-1999</i> .....	22
<i>TABLE 6 CONSENTED ORGANS NOT RECOVERED, 1995-1999</i> .....	22
BETTER HARVESTING.....	22
Papworth Cocktail .....	23
Remembering the Ultimate Customer, the Patient on the Waiting List.....	24

LESS WASTE.....	24
PRESERVATION .....	25
Rinse/Preservation Solutions .....	25
TABLE 7 MAJOR ORGAN PRESERVATION SOLUTIONS .....	26
Collins Solution.....	26
Viaspan.....	26
Celsior.....	26
Custodiol.....	27
TABLE 8 THE NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTION (EXCEPT PAPWORK COCKTAIL), THROUGH 2007 .....	27
Market Size .....	27
Potential New Alternatives .....	28
Machine Perfusion.....	28
Waters Medical Systems .....	29
Bio-Preserve International.....	29
TransMedics, Inc.....	30
NON-HEART-BEATING DONORS .....	30
TESTING.....	31
Blood Typing .....	31
Tissue Typing.....	31
Panel Reactive Antibodies (PRA).....	32
TABLE 9 TYPES OF TYPING.....	32
Advances .....	33
TABLE 10 PLAYERS IN THE HLA TYPING MARKET.....	33
The Market for Histocompatibility Supplies and Services .....	34
TABLE 11 THE U.S. MARKET FOR TISSUE TYPING SERVICES, THROUGH 2007 (\$ MILLIONS).....	35
Splitting the Market.....	35
Regulation.....	35
Plasmapheresis: Transplantation without Matching Antigens.....	35
Post-Transplant .....	36
Biotronik.....	36
Isis .....	36
Data Sciences .....	36
Reperfusion Injury .....	36
FIGHTING REJECTION.....	37
TABLE 12 NUMBER OF PATIENTS IN THE U.S. WHO ARE ON WAITING LIST BECAUSE OF GRAFT FAILURE (FAILURE OF PREVIOUSLY TRANSPLANTED ORGAN), ALL ORGANS, 1995-1999.....	37
TABLE 13 PERCENT OF U.S. PATIENTS ON WAITING LIST BY ORGAN WHO HAD A PREVIOUS TRANSPLANT, 1995-1999 (%).....	38
TABLE 14 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT, ALL ORGANS, 1995-1999.....	38
Immunosuppression .....	39
Market Size .....	39
TABLE 15 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION, THROUGH 2007.....	40

<i>TABLE 16 WORLDWIDE SALES OF IMMUNOSUPPRESSIVES BY COMPANY, 1999-2001 (\$ MILLIONS)</i> .....	40
Crowded Market .....	40
Five Types of Immunosuppressives .....	41
<i>TABLE 17 U.S. SALES OF IMMUNOSUPPRESSIVES BY TYPE, THROUGH 2007* (\$ MILLIONS)</i> .....	41
<i>FIGURE 2 U.S. SALES OF IMMUNOSUPPRESSIVES BY TYPE, 1999-2007 (\$ MILLIONS)</i> .....	42
<i>TABLE 18 WORLD SALES OF IMMUNOSUPPRESSIVE BY TYPE, THROUGH 2007 (\$ MILLIONS)</i> .....	42
Antiproliferatives .....	42
Calcineurin Inhibitors .....	43
Calcineurin Inhibitors (Continued).....	44
Antibodies .....	45
TOR Inhibitors .....	46
<i>TABLE 19 EXPERIMENTAL IMMUNOSUPPRESSIVES BY TYPE</i> .....	47
Clinical Testing .....	48
Generics.....	48
GOVERNORS, CORPORATE EXECUTIVES WANT TO LET GENERIC COMPETE SOONER .....	49
Governors, Corporate Executives Want to Let Generics Compete Sooner (Continued) .....	50
EFFECT OF SHORTER MONOPOLY TIMES ON TRANSPLANTATION DRUG RESEARCH .....	51
STATE PROSECUTORS TARGET DRUG MAKERS .....	51
INTERNATIONAL PATENT RIGHTS .....	52
TRIPS.....	52
Impact of Waste Reduction on Supply .....	53
Transplantation without Rejection .....	53
Tolerance .....	53
Antisense Therapy .....	53
Costimulation.....	54
Chimerism .....	55
University of Pittsburgh .....	55
Massachusetts General Hospital and BioTransplant.....	56
Abgenix .....	57
Chimeric Therapies .....	57
Insurance .....	57
Fighting Infections .....	58
<i>TABLE 20 COMMON POST-TRANSPLANT INFECTIONS</i> .....	58
<i>TABLE 21 COMMON POST-TRANSPLANT DRUGS</i> .....	58
<i>TABLE 21 (CONTINUED)</i> .....	59
<i>TABLE 22 COST OF TRANSPLANT ANTIBIOTICS IN THE U.S., THROUGH 2007 (\$ MILLIONS)</i> .....	59
Monitoring .....	59

<i>TABLE 23 THE WORLD MARKET FOR TRANSPLANT DRUG AND DISEASE MONITORING AGENTS, THROUGH 2007 (\$ MILLIONS)</i> .....	60
THE EFFICIENCY DIVIDEND.....	60
<i>TABLE 24 MAXIMUM POTENTIAL FOR ADDITIONAL ORGANS COMPARED TO DEMAND IN THE U.S., 1999</i> .....	61
TISSUE.....	61
FINDING MORE SUPPLY.....	61
EXPANDING TRADITIONAL SOURCES: GETTING MORE	
CADAVERS.....	61
Spain Sets Donation Standard.....	62
<i>TABLE 25 INTERNATIONAL ORGAN DONOR RATES, 2000 (PER MILLION OF POPULATION)</i> .....	62
Even with Increased Donation, Waiting Lists Persist.....	63
<i>TABLE 26 TRANSPLANTATIONS AND WAITING LIST NUMBERS IN SPAIN, 2000</i> .....	63
Reforms to Boost Donation.....	64
Presumed Consent.....	64
<i>TABLE 27 SELECTED COUNTRIES AND TYPE OF CONSENT</i> .....	65
Donor Compensation.....	65
TAPPING NEW SOURCES: EXPANDING DONATION TO	
NEW NATIONS AND LIVING DONORS.....	66
Shifting Cadaveric Donation.....	67
<i>TABLE 28 COUNTRIES WITH KIDNEY TRANSPLANT PROGRAMS</i> .....	67
<i>TABLE 28 (CONTINUED)</i> .....	68
The Argentinean Collapse.....	68
<i>TABLE 29 KIDNEY, LIVER, HEART TRANSPLANTS BY REGION, 2000</i> .....	69
<i>TABLE 29 (CONTINUED)</i> .....	70
More Competition Splinters Market.....	70
Organ Selling Meets Dammed Up Demand.....	70
Marketing Availability.....	71
Belgium and Austria.....	71
Costa Rica.....	71
South Africa.....	72
Pakistan.....	72
Cuba.....	72
Tissues.....	72
Effects of Globalization.....	73
Living Donors.....	73
<i>TABLE 30 TRENDS IN LIVING AND CADAVERIC DONATION IN THE U.S., THROUGH 2007</i> .....	74
Kidney Exchanges.....	74
Reimbursement for Costs.....	75
NEW TECHNOLOGIES.....	76
ORGANS FROM ANIMALS: XENOTRANSPLANTATION.....	76
Overcoming Hyperacute Rejection.....	76
Porcine Endogenous Retrovirus.....	76
Major Competitors.....	77
Political Problems.....	77

ARTIFICIAL ORGANS .....	78
REDUCING DEMAND .....	78
CELLULAR TRANSPLANTS .....	78
THE CHALLENGE OF AGING POPULATIONS .....	79
<i>TABLE 31 GROWTH OF SELECTED POPULATION GROUPS IN THE U.S., THROUGH 2007 (MILLIONS) .....</i>	<i>79</i>
ORGANS .....	80
KIDNEYS .....	80
<i>TABLE 32 NUMBER OF KIDNEY TRANSPLANTATIONS BY REGION, THROUGH 2007 .....</i>	<i>80</i>
<i>TABLE 33 THE U.S. KIDNEY TRANSPLANT MARKET, THROUGH 2007 (\$ MILLIONS) .....</i>	<i>81</i>
<i>FIGURE 3 THE U.S. KIDNEY TRANSPLANT MARKET, 2002-2007 (\$ MILLIONS).....</i>	<i>81</i>
<i>TABLE 34 THE TOP FOUR KIDNEY TRANSPLANT PROGRAMS IN THE U.S., 2000 (BY NUMBER OF PROCEDURES) .....</i>	<i>82</i>
<i>TABLE 35 KIDNEY PATIENT AND GRAFT SURVIVAL, U.S. (%).....</i>	<i>82</i>
<i>TABLE 36 COSTS PER YEAR DUE TO END STAGE RENAL DISEASE, 1995-1999.....</i>	<i>82</i>
TRANSPLANTATION TOO RARE TO BE A SOLUTION .....	83
<i>TABLE 37 WAITING LIST TRENDS BY REGION, THROUGH 2007.....</i>	<i>83</i>
Shortage Is Worse in Japan .....	83
CADAVERIC DONATIONS FALLING.....	84
<i>TABLE 38 NUMBER OF KIDNEY TRANSPLANTATIONS IN THE U.S. FROM LIVING AND CADAVERIC DONORS, THROUGH 2007 .....</i>	<i>84</i>
<i>TABLE 39 KIDNEY TRANSPLANTATION IN NORWAY FROM LIVING AND CADAVERIC DONORS, THROUGH 2007 .....</i>	<i>84</i>
CLOSING THE KIDNEY GAP .....	85
INDICATIONS .....	85
<i>TABLE 40 LEADING CAUSES OF KIDNEY FAILURE (%).....</i>	<i>86</i>
<i>TABLE 41 LEADING CAUSES OF KIDNEY TRANSPLANTATION (%).....</i>	<i>86</i>
INTERNATIONAL TRENDS .....	86
OLDER RECIPIENTS .....	87
LESS REJECTION .....	87
<i>TABLE 42 HAZARD RATIO FOR GRAFT FAILURE (1993 = 1).....</i>	<i>87</i>
IMMUNOSUPPRESSION .....	88
<i>TABLE 43 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2007.....</i>	<i>88</i>
ADVANCES .....	89
Chimerism.....	89
ALTERNATIVES .....	90
Mechanical .....	90
Medical .....	90
Animal.....	91
Cellular .....	91
PANCREAS .....	91
<i>TABLE 44 GROWTH OF WHOLE PANCREAS TRANSPLANTATION, THROUGH 2007 .....</i>	<i>92</i>
<i>TABLE 45 U.S. WHOLE PANCREAS TRANSPLANTATION MARKET, THROUGH 2007 (\$ MILLIONS).....</i>	<i>92</i>

<i>FIGURE 4 U.S. WHOLE PANCREAS TRANSPLANTATION MARKET, 2000-2007 (\$ MILLIONS)</i> .....	92
<i>TABLE 46 THE TOP FOUR PANCREAS TRANSPLANT PROGRAMS IN THE U.S., 2000 (NUMBER OF TRANSPLANTS)</i> .....	93
ISLET CELLS .....	93
<i>TABLE 47 INTERNATIONAL AND U.S. PANCREAS GRAFT SURVIVAL RATES (%)</i> .....	94
A Breakthrough .....	94
Juvenile Diabetes Research Foundation .....	95
Drawbacks.....	95
<i>TABLE 48 PANCREAS WAITING LIST, U.S., THROUGH 2007</i> .....	96
Immunosuppression .....	96
Controversy.....	97
INDICATIONS .....	97
ALTERNATIVES .....	98
Cell Encapsulation.....	98
Biohybrid Technologies.....	98
Circe Biomedical .....	98
Islet Technologies.....	99
Cultured Stem Cells .....	99
Medical.....	99
Nuerochem .....	99
Columbia University.....	100
COSTS .....	100
LIVER.....	100
NUMBERS .....	101
<i>TABLE 49 GROWTH IN LIVER TRANSPLANTS BY REGION, THROUGH 2007</i> .....	101
<i>TABLE 50 LIVER TRANSPLANT MARKET IN THE U.S., THROUGH 2007 (\$ MILLIONS)</i> .....	102
<i>FIGURE 5 LIVER TRANSPLANT MARKET IN THE U.S., 2000-2007 (\$ MILLIONS)</i> .....	102
<i>TABLE 51 THE TOP FOUR LIVER TRANSPLANT PROGRAMS IN THE U.S., 2000</i> .....	103
DONORS.....	103
<i>TABLE 52 TRENDS IN LIVING DONOR LIVER TRANSPLANTS IN THE U.S.</i> .....	104
WAITING LIST .....	104
<i>TABLE 53 GROWTH IN LIVER WAITING LISTS BY REGION, THROUGH 2007</i> .....	104
<i>TABLE 54 DEATHS ON LIVER WAITING LIST, U.S., THROUGH 2007</i> .....	105
INDICATIONS .....	105
Causes of Cirrhosis.....	105
TISSUE TYPING .....	106
ORGAN RECOVERY .....	106
REJECTION.....	106
<i>TABLE 55 LIVER TRANSPLANT SURVIVAL RATES* (%)</i> .....	107
<i>TABLE 56 THE U.S. MARKET FOR IMMUNOSUPPRESSANTS AFTER LIVER TRANSPLANTATION, FIRST YEAR AFTER TRANSPLANT THROUGH 2007 (\$ MILLIONS)</i> .....	107
HEPATITIS B.....	108
HISTORY.....	108
CONTROVERSIES .....	109

Liver Allocation .....	109
ALTERNATIVES .....	109
Medical.....	109
Artificial Livers.....	110
Chemical-Mechanical Livers .....	110
HemoTherapies .....	110
HemoCleanse.....	111
Bioartificial Livers .....	111
Cedars-Sinai Medical Center .....	111
Circe Biomedical .....	111
Algenix .....	112
Excorp Medical.....	112
Exten Corp.....	112
Organogenesis .....	113
Vitagen.....	113
Relative Costs .....	113
TABLE 57 TREATMENT COSTS FOR ACUTE LIVER FAILURE: TRANSPLANTATION AND BIOARTIFICIAL LIVER, U.S., THROUGH 2007 (\$ MILLIONS) .....	113
FIGURE 6 TREATMENT COSTS FOR ACUTE LIVER FAILURE: TRANSPLANTATION AND BIOARTIFICIAL LIVER, U.S., 2000-2007 (\$ MILLIONS) .....	114
Regeneration Therapy .....	114
HEART .....	114
TABLE 58 DECLINING NUMBERS IN HEART TRANSPLANTATION BY REGION, THROUGH 2007.....	115
TABLE 59 U.S. HEART TRANSPLANT MARKET, THROUGH 2007 (\$ MILLIONS).....	115
TABLE 60 TOP FOUR U.S. HEART TRANSPLANT PROGRAMS, 2000.....	116
FEWER TRANSPLANTS DUE TO TIGHTER SUPPLY .....	116
Cultural Backlash.....	116
Peak Year Was 1995 .....	117
WAITING LISTS ALSO SHRINK.....	118
TABLE 61 HEART WAITING LIST TRENDS, THROUGH 2007.....	118
Are Waiting List and Transplant Numbers Inflated?.....	118
HEART-LUNG NUMBERS .....	119
TABLE 62 TRENDS IN HEART-LUNG TRANSPLANTATION BY REGION, THROUGH 2007.....	119
TABLE 63 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2007 (\$ MILLIONS) .....	120
FIGURE 7 U.S. HEART-LUNG TRANSPLANT MARKET, 2000-2007 (\$ MILLIONS).....	120
TABLE 64 THE TOP THREE U.S. COMBINED HEART-LUNG TRANSPLANT PROGRAMS, 2000 .....	121
TABLE 65 HEART-LUNG WAITING LIST TRENDS, THROUGH 2007 .....	121
REJECTION .....	122
TABLE 66 INTERNATIONAL HEART AND LUNG TRANSPLANT PATIENT SURVIVAL RATES (%) .....	122
TABLE 67 THE U.S. MARKET FOR ANTI-REJECTION DRUGS AFTER HEART TRANSPLANTATION, FIRST YEAR AFTER TRANSPLANT (\$ MILLIONS).....	123



INDICATIONS .....	123
<i>TABLE 68 LEADING CAUSES OF HEART FAILURE (%) .....</i>	<i>123</i>
TISSUE TYPING .....	124
PRESERVATION .....	124
ALTERNATIVES .....	124
Medical .....	124
Cholesterol Vaccine.....	125
Endothelian Antagonists .....	125
Animal.....	125
Surgical .....	126
Laser Revascularization .....	126
Mitral Valve Repair .....	127
Cardiac Support Devices .....	127
Mechanical .....	128
Thoratec.....	129
World Heart Corp. ....	129
Micromed.....	130
VAD Market.....	130
Abiomed.....	130
Regeneration Trumps Replacement.....	131
Cellular .....	131
BioHeart .....	131
LUNGS .....	132
<i>TABLE 69 TRENDS IN LUNG TRANSPLANTATIONS BY REGION, THROUGH 2007 .....</i>	<i>132</i>
<i>TABLE 70 U.S. LUNG TRANSPLANTATION MARKET, THROUGH 2007 (\$</i>	
<i>MILLIONS) .....</i>	<i>133</i>
<i>FIGURE 8 U.S. LUNG TRANSPLANTATION MARKET, 2000-2007 (\$ MILLIONS) .....</i>	<i>133</i>
<i>TABLE 71 THE TOP FOUR U.S. LUNG TRANSPLANT PROGRAMS, 2000.....</i>	<i>134</i>
DONATION .....	134
<i>TABLE 72 RECOVERED ORGANS NOT USED, 1995-1999, U.S.....</i>	<i>134</i>
WAITING LISTS .....	135
<i>TABLE 73 LUNG WAITING LIST TRENDS, THROUGH 2007.....</i>	<i>135</i>
<i>TABLE 74 REPORTED DEATHS ON LUNG WAITING LIST IN U.S., 1998-2001.....</i>	<i>136</i>
REJECTION .....	136
<i>TABLE 75 INTERNATIONAL AND U.S. LUNG TRANSPLANT AND GRAFT</i>	
<i>SURVIVAL RATES* (%) .....</i>	<i>136</i>
<i>TABLE 76 THE U.S. MARKET FOR ANTI-REJECTION DRUGS AFTER LUNG</i>	
<i>TRANSPLANTATION, FIRST YEAR AFTER TRANSPLANT (\$ MILLIONS).....</i>	<i>137</i>
INDICATIONS .....	137
<i>TABLE 77 LEADING CAUSES OF CHRONIC LUNG FAILURE, 1995-1999 (%).....</i>	<i>137</i>
PRESERVATION .....	138
Celsior .....	138
Hypothermosol.....	139
21 <sup>st</sup> Century Medicine .....	139
HISTORY.....	139
ALTERNATIVES .....	140
Medical.....	140

Retinoic Acid .....	140
Surgical .....	141
Cellular .....	141
INTESTINES .....	141
TABLE 78 TRENDS IN SMALL BOWEL TRANSPLANTATION, U.S., THROUGH 2007 .....	142
TABLE 79 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2007 (\$ MILLIONS) .....	142
FIGURE 9 U.S. SMALL BOWEL TRANSPLANTATION MARKET, 2000-2007 (\$ MILLIONS) .....	143
TABLE 80 THE TOP FOUR U.S. SMALL BOWEL TRANSPLANT PROGRAMS, 2000.....	143
POISED FOR GROWTH.....	144
TABLE 81 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS.....	144
REJECTION .....	144
TABLE 82 INTERNATIONAL INTESTINE TRANSPLANT SURVIVAL RATES (%) .....	145
TYPES OF TRANSPLANTS .....	145
TABLE 83 LEADING CAUSES OF INTESTINE FAILURE (%) .....	146
INDICATIONS .....	146
Immunosuppression .....	147
TABLE 84 THE U.S. MARKET FOR ANTI-REJECTION DRUGS AFTER SMALL BOWEL TRANSPLANTATION, FIRST YEAR AFTER TRANSPLANTATION (\$ MILLIONS) .....	147
Patient Follow-up.....	147
HISTORY.....	148
ALTERNATIVES .....	148
Medical.....	148
Mechanical.....	148
Cellular .....	148
TISSUES .....	149
EYES .....	149
CORNEA.....	149
TABLE 85 CORNEAL TRANSPLANTS IN SPECIFIED COUNTRIES, 1997-2000 .....	149
TABLE 86 CORNEAL TRANSPLANTS AND MARKET IN THE U.S., THROUGH 2007 .....	150
FIGURE 10 CORNEAL TRANSPLANTS AND MARKET IN THE U.S., 2001-2007 (\$ MILLIONS) .....	150
Donors .....	151
TABLE 87 NUMBER OF CORNEA DONORS IN U.S. ....	151
Waiting List .....	151
U.S. ....	151
Other Countries .....	151
Indications .....	152
Tissue Testing.....	152
Preservation.....	153
Cryopreservation.....	153
Immunosuppression .....	154
History.....	154
Alternatives .....	155

Surgical .....	155
Synthetic .....	155
RETINAL DEGENERATION .....	156
Cellular Transplants .....	156
Gene Therapy.....	157
Electronic Implants .....	157
BLOOD STEM CELLS .....	158
NUMBERS .....	158
TABLE 88 BONE MARROW TRANSPLANTS, U.S., 1995-1999 .....	159
TABLE 89 PROJECTED U.S. BONE MARROW TRANSPLANT PROCEDURES, THROUGH 2007.....	159
Autologous Passes Allogenic .....	159
TABLE 90 WORLDWIDE BLOOD AND BONE MARROW TRANSPLANT PATIENTS, 1995-1998.....	160
TABLE 91 PROJECTED WORLDWIDE BLOOD AND BONE MARROW TRANSPLANT PATIENTS, THROUGH 2007.....	160
Less Bone Marrow .....	161
Older Patients.....	161
DONORS.....	161
TABLE 92 HOME COUNTRIES OF BMDW MEMBERS.....	162
Potential for HLA Testing.....	163
TABLE 93 THE NUMBER OF BONE MARROW DONORS PER 10,000 INHABITANTS.....	163
TABLE 93 (CONTINUED).....	164
WAITING LIST .....	164
REJECTION.....	164
TABLE 94 U.S. MARKET FOR IMMUNOSUPPRESSANTS AFTER BLOOD STEM CELL TRANSPLANTATION, THROUGH 2007 (\$ MILLIONS).....	165
INDICATIONS .....	165
CELL SEPARATION SYSTEMS.....	166
IMMUNOSUPPRESSION .....	166
Abgenix .....	167
Biotransplant.....	167
Chimeric Therapies .....	167
Enzo Biochem .....	168
Protein Design Labs .....	168
Repligen .....	168
University of Pennsylvania .....	168
HISTORY.....	169
First Successful Transplant .....	169
Donor Registry Established.....	170
Cord Blood.....	171
ALTERNATIVES .....	171
Expanding Cord Blood.....	172
Replicell.....	172
BONES .....	173
TABLE 95 DOMINANT BONE REPLACEMENT PROCEDURES, U.S., 1995-1999.....	173

<i>TABLE 96 PROJECTED MAJOR BONE REPLACEMENT PROCEDURES, U.S., THROUGH 2007</i> .....	174
PROCEDURES.....	174
MARKET TOTALS.....	175
<i>TABLE 97 U.S. AND WORLDWIDE IMPLANT MARKET GROWTH, THROUGH 2007 (\$ BILLIONS)</i> .....	175
<i>FIGURE 11 U.S. AND WORLDWIDE IMPLANT MARKET GROWTH, 2002-2007 (\$ BILLIONS)</i> .....	175
Bone Allografts .....	175
<i>TABLE 98 U.S. AND WORLD VALUES OF BONE ALLOGRAFT MARKET, THROUGH 2007 (\$ MILLIONS)</i> .....	176
<i>FIGURE 12 U.S. AND WORLD VALUES OF BONE ALLOGRAFT MARKET, 2002-2007 (\$ MILLIONS)</i> .....	177
Products.....	177
Demineralized Bone Matrix .....	178
Machined Implants .....	178
<i>TABLE 99 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2007 (\$ MILLIONS)</i> .....	178
<i>FIGURE 13 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, 2000-2007 (\$ MILLIONS)</i> .....	179
DONORS.....	179
Mandatory Referrals .....	179
Public Cynicism .....	180
Donor Compensation .....	181
INDICATIONS .....	181
TISSUE TESTING .....	182
Preventing Infection .....	183
PRESERVATION .....	183
HISTORY.....	184
COMPETITION.....	185
ALTERNATIVES .....	186
Animal Bone Grafts.....	186
Medical.....	186
Synthetics .....	186
Orthovita .....	187
Exactech .....	187
Spine Wave.....	187
Regeneration.....	188
Bone-Growth Factors.....	188
Medtronic.....	188
Collagen Sponges.....	189
Chrysalin.....	189
Bone Marrow.....	189
Peripheral Blood Stem Cells .....	190
Meniscus Allografts .....	190
Collagen Alternative.....	190
REGULATION .....	191

State Regulation .....	191
Rules for Obtaining Consent.....	192
REPLACEMENT HEART VALVES, ARTERIES AND OTHER	
VESSELS .....	193
TABLE 100 NUMBER OF HEART VALVE TRANSPLANTS AND BYPASS	
OPERATIONS IN THE U.S., 1995-1999.....	193
HEART VALVE ALLOGRAFT MARKET .....	194
TABLE 101 U.S. AND WORLD HEART VALVE TRANSPLANT MARKET, THROUGH	
2007.....	194
Tissue Valves Gain Popularity.....	194
Major Competitors.....	195
VASCULAR GRAFTS .....	196
TABLE 102 PROJECTED NUMBER OF HEART VALVE TRANSPLANTS AND	
BYPASS OPERATIONS IN THE U.S., THROUGH 2007.....	196
DONORS.....	197
Valves from Morgues .....	197
Public Cynicism .....	198
International Trade .....	198
WAITING LIST .....	198
INDICATIONS .....	198
Heart Valves .....	198
Vascular Grafts.....	199
TISSUE TESTING .....	199
PRESERVATION/PROCESSING .....	200
HISTORY.....	200
Synthetics .....	200
Xenografts.....	201
Defects and Regulation.....	201
ADVANCES.....	202
Heart Valves .....	202
Vascular Grafts.....	202
ALTERNATIVES .....	203
Animal.....	203
Heart Valves .....	203
Stentless Valves .....	203
Calcification .....	204
Surgical .....	204
Heart Valves .....	204
Coronary Bypass Grafts .....	205
Medical.....	205
Heart Valve and Vascular Disease .....	205
Mechanical/Synthetic .....	206
Heart Valves .....	206
Improving Blood Flow.....	207
Better Maintenance .....	207

Tri-Leaflet Valve .....	207
Vascular Grafts .....	208
Minimally Invasive Surgery .....	208
Engineered Tissue .....	208
Heart Valves .....	208
Vascular Grafts .....	209
Gene Therapy .....	209
SKIN, MUSCLE, AND MATRIX .....	210
TABLE 103 U.S. MARKET OF HUMAN SKIN-BASED PRODUCTS, THROUGH 2007.....	210
SKIN .....	210
Indications .....	211
TABLE 104 SKIN GRAFTS IN THE U.S., 1995-1999.....	212
Burns .....	213
Wounds .....	214
Venous Ulcers .....	214
TABLE 105 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE OVER 64 POPULATION, U.S., THROUGH 2007.....	214
Diabetic Ulcers .....	214
TABLE 106 ESTIMATED INCIDENCE OF DIABETIC FOOT ULCERS, U.S. ....	215
Pressure Ulcers .....	215
Urinary Incontinence and Other Uses .....	215
TABLE 107 TENDON, CARTILAGE, AND MUSCLE GRAFTS, U.S., 1995-1999 .....	215
Cosmetic Surgery .....	216
TABLE 108 COSMETIC SURGERY TRENDS IN THE U.S., 1997-2001 .....	216
TABLE 109 GROWTH IN U.S. OF POPULAR COSMETIC SURGERIES MAKING USE OF DONATED HUMAN TISSUE, 1999-2001 .....	216
TABLE 110 PROJECTED GROWTH IN POPULAR U.S. COSMETIC SURGERY MARKETS FOR SKIN PRODUCTS, THROUGH 2007 (NUMBER OF PROCEDURES) .....	217
DONORS .....	217
Public Cynicism .....	217
WAITING LIST .....	218
REJECTION .....	218
TISSUE TESTING .....	218
PRESERVATION .....	219
HISTORY .....	219
ALTERNATIVES .....	220
Animals .....	220
Biobrane .....	221
Oasis .....	221
Medical .....	222
Repifermin .....	222
Telomerase .....	222
Ulcer Inspections .....	222
Botox .....	223
Synthetic .....	223

AlloDerm .....	223
Integra .....	224
TransCyte .....	225
Dermagraft .....	225
Apligraf .....	225
OrCel .....	226
Promogran Matrix Wound Dressing .....	226
Other Uses .....	226
Next Generation Products .....	227
Cultured Autologous Skin .....	227
Shriners Burn Hospital .....	228
OTHER RESEARCH .....	228
REGULATION .....	228
CELLULAR TRANSPLANTATION .....	229
FOUR TYPES OF CELLS OFFER POTENTIAL .....	229
NUMBERS .....	230
DONORS .....	230
REJECTION .....	231
INDICATIONS .....	231
HISTORY .....	231
Cancer Cells .....	232
Restrictions .....	232
CELLULAR PATENTS .....	233
NEW RULE REQUIRES SHOWING OF SPECIFIC AND SUBSTANTIAL UTILITY .....	234
COURTS JOIN NARROWING TREND .....	235
Festo Limits Doctrine of Equivalents .....	235
Ranbaxy Takes One from GlaxoSmithKline .....	236
Closer Look at Obviousness .....	236
Crowded Race Field .....	236
ALTERNATIVES .....	237
COMPANY DIRECTORY .....	238
AASTROM BIOSCIENCES, INC. ....	238
ABGENIX .....	238
ABIOMED .....	238
ACORN CARDIOVASCULAR, INC. ....	238
ADVANCED CELL TECHNOLOGY .....	239
ADVANCED TISSUE SCIENCES .....	239
ALEXION PHARMACEUTICAL .....	239
ALGENIX .....	239
ALLOSOURCE .....	239
AMGEN .....	240
AORTECH INTERNATIONAL .....	240
APOTEX CORPORATION USA .....	240

ARGUS BIOMEDICAL PTY .....	240
ARIAD PHARMACEUTICALS .....	240
ARROW INTERNATIONAL .....	241
ATS MEDICAL INC.....	241
AVANT IMMUNOTHERAPEUTICS.....	241
AVAX TECHNOLOGIES.....	241
AVENTIS PHARMA US .....	241
BARR LABORATORIES.....	242
BAUSCH & LOMB .....	242
BAXTER INTERNATIONAL INC. ....	242
BERTEK PHARMACEUTICAL.....	242
BIO ARRAY SOLUTIONS.....	242
BIOHEART, INC.....	243
BIOHYBRID TECHNOLOGIES .....	243
BIOLIFE TECHNOLOGIES, INC. ....	243
BIOTEST DIAGNOSTICS CORP. ....	243
BIOTRANSPLANT .....	243
BIOTRONIK, INC.....	244
CARDIOGENESIS.....	244
CARDION PHARMACEUTICALS, INC.....	244
CARDIOWEST TECHNOLOGIES .....	244
CHIMERIC THERAPIES .....	244
CHRYSALIS BIOTECHNOLOGY .....	244
CIRCE BIOMEDICAL, INC. ....	245
COOK BIOTECHNOLOGY.....	245
CORIXA CORP.....	245
CR BARD.....	245
CRYOLIFE.....	245
CURIS.....	246
DEPUY ACROMED, INC. ....	246
DIACRIN .....	246
DIGENE .....	246
DYNAL BIOTECH.....	246
EDWARDS LIFE SCIENCES .....	247
ENZO BIOCHEM.....	247
ENZON .....	247
EON LABS, INC. ....	247
EXACTECH, INC.....	247
EXCORP .....	248
EXTEN INDUSTRIES.....	248
FUJISAWA HEALTHCARE, INC.....	248
GENENTECH .....	248
GENOVISION.....	248
GENZYME .....	249



GENZYME TRANSGENICS CORP.....	249
GERON CORP. ....	249
GTI, INC.....	249
GUIDANT.....	249
HEMOCLEANSE.....	250
HEMOTHERAPIES.....	250
INCARA PHARMACEUTICALS.....	250
INFIGEN .....	250
IMMERGE BIOTHERAPEUTICS .....	250
ILEX ONCOLOGY .....	250
IMMUCOR .....	251
IMMUNEX .....	251
INNOGENETICS, INC.....	251
INTEGRA LIFE SCIENCES .....	251
INTERPORE CROSS INTERNATIONAL.....	251
ISIS PHARMACEUTICALS, INC.....	252
ISLET TECHNOLOGIES .....	252
ISOTIS.....	252
KRITON MEDICAL.....	252
L-VAD TECHNOLOGY, INC. ....	252
LAYTON BIOSCIENCE .....	253
LIFECELL CORP. ....	253
LIFENET.....	253
MAST DIAGNOSTIC.....	253
MEDIMMUNE .....	254
MEDTRONIC .....	254
MERCK & CO., INC. ....	254
MICROMED TECHNOLOGY INC. ....	254
MUSKULOSKELETAL TRANSPLANT FOUNDATION (MTF) .....	254
NATIONAL GENETICS INSTITUTE .....	255
NEXTRAN.....	255
NIPPON KAYAKU CO. ....	255
NOVAMONT .....	255
NUEROCHEM INC. ....	255
NOVARTIS PHARMACEUTICAL.....	256
ODYSSEY PHARMACEUTICALS, INC.....	256
ONE LAMBDA.....	256
ORCHID BIOSCIENCES .....	256
ORGANOGENESIS .....	256
ORQUEST, INC. ....	257
ORTEC INTERNATIONAL, INC.....	257
ORTHO BIOTECH PRODUCTS, L.P. ....	257
ORTHOLOGIC CORP.....	257
ORTHOVITA.....	257

PARADIGM GENETICS .....	258
PEL-FREEZ CLINICAL SYSTEMS, LLC .....	258
PHARMACIA CORPORATION.....	258
PPL THERAPEUTICS PLC .....	258
PROMETHEUS LABORATORIES INC. ....	258
PROTEIN DESIGN LABS.....	259
PROTEIN POLYMER TECHNOLOGIES, INC. ....	259
PYROSEQUENCING AB .....	259
QUEST DIAGNOSTICS .....	259
QUESTCOR PHARMACEUTICALS, INC. ....	259
REGEN BIOLOGICS.....	260
REGENERATION TECHNOLOGIES .....	260
REPLIGEN.....	260
ROBBINS SCIENTIFIC .....	260
ROCHE (F. HOFFMANN-LA ROCHE LTD).....	260
ROXANE LABORATORIES, INC. ....	261
ST. JUDE MEDICAL.....	261
SANGSTAT .....	261
SELECT THERAPEUTICS .....	261
SIDMAK .....	261
SNIA GROUP .....	262
SPINAL CONCEPTS, INC. ....	262
SPINE WAVE, INC.....	262
STEM CELLS, INC.....	262
STEM CELL TECHNOLOGIES .....	262
STYKER CORPORATION.....	263
SULZER CARBOMEDICS .....	263
SULZER ORTHOPEDICS.....	263
SULZER SPINE-TECH .....	263
TANOX .....	263
THORATEC.....	264
TUTOGEN MEDICAL, INC. ....	264
TWENTY-FIRST CENTURY MEDICINE.....	264
VITAGEN .....	264
WATERS MEDICAL SYSTEMS .....	264
WORLD HEART CORP. ....	265
WYETH (FORMERLY AMERICAN HOME PRODUCTS).....	265